|
|
|
|
LEADER |
01000naa a22002652 4500 |
001 |
NLM351130594 |
003 |
DE-627 |
005 |
20231226050615.0 |
007 |
cr uuu---uuuuu |
008 |
231226s2023 xx |||||o 00| ||eng c |
024 |
7 |
|
|a 10.2144/btn-2022-0045
|2 doi
|
028 |
5 |
2 |
|a pubmed24n1170.xml
|
035 |
|
|
|a (DE-627)NLM351130594
|
035 |
|
|
|a (NLM)36601888
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
100 |
1 |
|
|a Hiseni, Pranvera
|e verfasserin
|4 aut
|
245 |
1 |
0 |
|a Prediction of high fecal propionate-to-butyrate ratios using 16S rRNA-based detection of bacterial groups with liquid array diagnostics
|
264 |
|
1 |
|c 2023
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a Date Completed 30.01.2023
|
500 |
|
|
|a Date Revised 14.02.2023
|
500 |
|
|
|a published: Print-Electronic
|
500 |
|
|
|a Citation Status MEDLINE
|
520 |
|
|
|a Butyrate and propionate represent two of three main short-chain fatty acids produced by the intestinal microbiota. In healthy populations, their levels are reportedly equimolar, whereas a deviation in their ratio has been observed in various diseased cohorts. Monitoring such a ratio represents a valuable metric; however, it remains a challenge to adopt short-chain fatty acid detection techniques in clinical settings because of the volatile nature of these acids. Here we aimed to estimate short-chain fatty acid information indirectly through a novel, simple quantitative PCR-compatible assay (liquid array diagnostics) targeting a limited number of microbiome 16S markers. Utilizing 15 liquid array diagnostics probes to target microbiome markers selected by a model that combines partial least squares and linear discriminant analysis, the classes (normal vs high propionate-to-butyrate ratio) separated at a threshold of 2.6 with a prediction accuracy of 96%
|
650 |
|
4 |
|a Journal Article
|
650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
650 |
|
4 |
|a LAD
|
650 |
|
4 |
|a SCFA
|
650 |
|
4 |
|a butyrate
|
650 |
|
4 |
|a gut microbiome
|
650 |
|
4 |
|a propionate
|
650 |
|
4 |
|a qPCR
|
650 |
|
7 |
|a Butyrates
|2 NLM
|
650 |
|
7 |
|a Propionates
|2 NLM
|
650 |
|
7 |
|a RNA, Ribosomal, 16S
|2 NLM
|
650 |
|
7 |
|a Fatty Acids, Volatile
|2 NLM
|
700 |
1 |
|
|a Snipen, Lars
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Wilson, Robert C
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Furu, Kari
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Hegge, Finn Terje
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Rudi, Knut
|e verfasserin
|4 aut
|
773 |
0 |
8 |
|i Enthalten in
|t BioTechniques
|d 1988
|g 74(2023), 1 vom: 18. Jan., Seite 9-21
|w (DE-627)NLM012627046
|x 1940-9818
|7 nnns
|
773 |
1 |
8 |
|g volume:74
|g year:2023
|g number:1
|g day:18
|g month:01
|g pages:9-21
|
856 |
4 |
0 |
|u http://dx.doi.org/10.2144/btn-2022-0045
|3 Volltext
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_NLM
|
912 |
|
|
|a GBV_ILN_21
|
912 |
|
|
|a GBV_ILN_22
|
912 |
|
|
|a GBV_ILN_39
|
912 |
|
|
|a GBV_ILN_40
|
912 |
|
|
|a GBV_ILN_50
|
912 |
|
|
|a GBV_ILN_60
|
912 |
|
|
|a GBV_ILN_62
|
912 |
|
|
|a GBV_ILN_65
|
912 |
|
|
|a GBV_ILN_70
|
912 |
|
|
|a GBV_ILN_99
|
912 |
|
|
|a GBV_ILN_121
|
912 |
|
|
|a GBV_ILN_130
|
912 |
|
|
|a GBV_ILN_227
|
912 |
|
|
|a GBV_ILN_350
|
912 |
|
|
|a GBV_ILN_618
|
912 |
|
|
|a GBV_ILN_640
|
912 |
|
|
|a GBV_ILN_754
|
912 |
|
|
|a GBV_ILN_2001
|
912 |
|
|
|a GBV_ILN_2002
|
912 |
|
|
|a GBV_ILN_2003
|
912 |
|
|
|a GBV_ILN_2005
|
912 |
|
|
|a GBV_ILN_2006
|
912 |
|
|
|a GBV_ILN_2007
|
912 |
|
|
|a GBV_ILN_2008
|
912 |
|
|
|a GBV_ILN_2009
|
912 |
|
|
|a GBV_ILN_2010
|
912 |
|
|
|a GBV_ILN_2012
|
912 |
|
|
|a GBV_ILN_2015
|
912 |
|
|
|a GBV_ILN_2018
|
912 |
|
|
|a GBV_ILN_2023
|
912 |
|
|
|a GBV_ILN_2035
|
912 |
|
|
|a GBV_ILN_2040
|
912 |
|
|
|a GBV_ILN_2060
|
912 |
|
|
|a GBV_ILN_2099
|
912 |
|
|
|a GBV_ILN_2105
|
912 |
|
|
|a GBV_ILN_2121
|
912 |
|
|
|a GBV_ILN_2470
|
951 |
|
|
|a AR
|
952 |
|
|
|d 74
|j 2023
|e 1
|b 18
|c 01
|h 9-21
|